Aclaris has enough cash to run a busy 2026 immunology catalyst calendar, but the company still has no approved wholly controlled product, recurring operating losses, ATM dilution, and several clinical proof gates that can change the story quickly.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
